Atrial Myxoma: Definition, Clinical Significance, and Overview

Posted on February 28, 2026 | by drheartcare

Atrial Myxoma Introduction (What it is)

Atrial Myxoma is a primary (originating in the heart) benign tumor that most often arises in the atria.
It is a cardiac pathology relevant to anatomy, hemodynamics, and embolic risk.
It is commonly discussed in cardiology, emergency care, and cardiothoracic surgery because it can mimic more common diseases.
It is most often identified on echocardiography and confirmed after surgical excision by pathology.

Clinical role and significance

Atrial Myxoma matters because it is a potentially serious cause of cardiac obstruction and systemic embolization despite being histologically benign. In practice, it sits at the intersection of structural heart disease, valvular physiology, and stroke/cardiac embolism evaluation.

Clinically, it is significant for several reasons:

Obstructive physiology: A left atrial mass can intermittently obstruct transmitral flow, producing signs and symptoms similar to mitral stenosis or heart failure, including exertional dyspnea, orthopnea, pulmonary edema, presyncope, or syncope.
Embolic risk: Tumor fragments or surface thrombus can embolize to the brain or systemic circulation, presenting as ischemic stroke, transient ischemic attack, acute limb ischemia, or organ infarction.
Mimicry and diagnostic pitfalls: Presentations may resemble atrial thrombus, infective endocarditis (especially when constitutional symptoms exist), or other intracardiac tumors, making accurate imaging interpretation important.
Surgical relevance: Management often involves cardiothoracic surgery for excision, with attention to perioperative assessment (e.g., rhythm monitoring for atrial fibrillation) and follow-up imaging for recurrence in selected cases.

For trainees, Atrial Myxoma is a classic exam topic because it connects symptoms to anatomy (especially the left atrium, interatrial septum, and mitral valve) and highlights why a “benign” diagnosis can still have urgent implications.

Indications / use cases

Atrial Myxoma is typically considered or discussed in these scenarios:

Evaluation of an intracardiac mass discovered on transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE).
Unexplained embolic stroke or systemic embolism, especially when routine sources (e.g., atrial fibrillation, carotid disease) are not evident.
Symptoms suggesting dynamic mitral inflow obstruction, such as positional dyspnea, syncope, or episodic pulmonary edema.
A new diastolic murmur or exam findings suggesting valvular obstruction without classic valve calcification.
Constitutional or inflammatory-type symptoms (e.g., fever, malaise, weight loss) where a cardiac source is part of the differential diagnosis.
Workup of suspected right-sided obstruction or embolization (e.g., signs mimicking tricuspid stenosis, or pulmonary embolic phenomena) when a right atrial mass is present.
Assessment in patients with features suggesting a familial syndrome (e.g., Carney complex) where cardiac tumors can recur or be multiple.

Contraindications / limitations

Atrial Myxoma itself is a diagnosis (a tumor), not a test or medication, so “contraindications” mainly apply to diagnostic approaches and interventions used to evaluate or treat it.

Key limitations and “not suitable” situations include:

Imaging limitations: TTE may have reduced sensitivity in patients with limited acoustic windows (e.g., obesity, lung hyperinflation), potentially requiring TEE, cardiac computed tomography (CT), or cardiac magnetic resonance imaging (MRI).
TEE limitations/contraindications: TEE may be deferred or avoided in some patients with significant esophageal disease or elevated aspiration risk. The choice varies by clinician and case.
CT/MRI limitations: CT involves ionizing radiation and iodinated contrast (relevant in contrast allergy or kidney dysfunction), while MRI may be limited by device compatibility and patient tolerance (e.g., severe claustrophobia). Details vary by device, material, and institution.
“Treating as thrombus” limitation: Empiric anticoagulation for a presumed thrombus may be inadequate if the mass is a myxoma; imaging features and clinical context guide decisions, and uncertainty may prompt multimodality imaging.
Surgical limitations: Definitive treatment is often surgical excision, but operative timing and candidacy depend on comorbidities, frailty, hemodynamic stability, and institutional resources.

How it works (Mechanism / physiology)

Atrial Myxoma produces clinical effects through mechanical, embolic, and systemic mechanisms.

Mechanical (obstructive) effects

Most atrial myxomas arise in the left atrium, commonly attached to the interatrial septum near the fossa ovalis region. When pedunculated and mobile, the tumor can prolapse toward the mitral valve during diastole, intermittently narrowing the effective mitral orifice. This can raise left atrial pressure, increase pulmonary venous pressure, and contribute to symptoms consistent with left-sided congestion.

Because obstruction may be dynamic and positional, symptoms can fluctuate with posture or activity. Unlike fixed valvular stenosis from calcification, the degree of obstruction may vary beat-to-beat depending on tumor mobility and cardiac cycle timing.

Embolic effects

The tumor surface can be friable, and thrombus may form on irregular tumor tissue. Either tumor fragments or thrombotic material can embolize. In left atrial tumors, emboli can reach the cerebral circulation (stroke) or systemic arterial beds. In right atrial tumors, embolization may enter the pulmonary circulation and mimic pulmonary embolism physiology.

Systemic (constitutional) effects

Some patients develop constitutional symptoms (e.g., fever, fatigue) and laboratory inflammatory findings. These features can blur the clinical picture with infections (including infective endocarditis) or autoimmune conditions. The exact symptom pattern varies by clinician and case, and not all patients exhibit systemic features.

Onset, duration, and reversibility

Atrial Myxoma tends to develop and enlarge over time, but the clinical onset may be abrupt if embolization occurs or if the tumor position causes sudden obstruction. Symptoms due to obstruction are often potentially reversible after tumor removal, while embolic complications (e.g., stroke) may have variable recovery depending on severity and timeliness of supportive care.

Atrial Myxoma Procedure or application overview

Atrial Myxoma is not a procedure; it is assessed and managed through a structured diagnostic-to-treatment workflow. A typical high-level sequence is:

Evaluation and exam – History focused on dyspnea, syncope/presyncope, embolic symptoms (neurologic deficits, limb pain), and constitutional complaints. – Physical exam may identify murmurs, signs of congestion, or rhythm irregularities (e.g., atrial fibrillation), but findings can be nonspecific.
Initial diagnostics – Electrocardiogram (ECG) to evaluate rhythm and conduction abnormalities. – Transthoracic echocardiography (TTE) as the usual first-line test to detect a mass, assess chamber size, valve function, and hemodynamics.
Defining anatomy and differential diagnosis – Transesophageal echocardiography (TEE) may better characterize attachment site, mobility, and relationship to the mitral valve and interatrial septum. – Cardiac MRI or cardiac CT may be used to improve tissue characterization, evaluate extracardiac anatomy, or clarify whether a mass is tumor versus thrombus, depending on availability and patient factors.
Preparation for intervention (when pursued) – Multidisciplinary planning often involves cardiology, anesthesia, and cardiothoracic surgery. – Additional testing may include assessment for coronary artery disease in appropriate patients and baseline labs, guided by institutional protocols.
Intervention – Surgical excision is commonly performed with removal of the tumor and evaluation of its attachment site. – The resected tissue is sent for pathologic confirmation to distinguish myxoma from other tumors (e.g., papillary fibroelastoma) or malignancy.
Immediate checks – Post-procedural echocardiography may be used to evaluate residual mass, valve function, and pericardial effusion, depending on the course and institutional practice. – Rhythm and hemodynamics are monitored for complications such as atrial arrhythmias.
Follow-up and monitoring – Follow-up plans vary by clinician and case and may include periodic echocardiography, especially when recurrence risk is a concern (e.g., familial syndromes, prior recurrence, multiple lesions).

Types / variations

Atrial Myxoma can be described by location, morphology, clinical presentation, and context.

By location

Left atrial myxoma: The most commonly encountered form; often associated with mitral inflow obstruction and systemic emboli.
Right atrial myxoma: May produce right-sided inflow obstruction physiology or pulmonary embolic phenomena.
Multiple or biatrial lesions: Less common; may raise suspicion for syndromic associations.

By morphology and mobility

Pedunculated (stalked) and mobile: More likely to cause intermittent obstruction and positional symptoms.
Sessile (broad-based) and less mobile: May present more with persistent obstruction or incidental discovery, though presentations vary.

By clinical pattern (classic triad framing)

Often taught as three overlapping patterns:

Obstructive symptoms: Dyspnea, syncope, pulmonary edema, signs resembling valvular disease.
Emolic events: Stroke or peripheral emboli; sometimes recurrent or multifocal.
Constitutional symptoms: Fever, malaise, weight loss; may mimic inflammatory or infectious disease.

Sporadic vs familial

Sporadic Atrial Myxoma: Most cases are isolated.
Familial/syndromic Atrial Myxoma: May occur as part of conditions such as Carney complex, where lesions can be multiple and recurrence risk is higher than in sporadic cases.

Advantages and limitations

Advantages (of recognizing and appropriately evaluating Atrial Myxoma):

Helps explain otherwise discordant symptoms, such as “mitral stenosis-like” signs without classic valve disease.
Provides a potentially unifying diagnosis for embolic events plus cardiac symptoms.
Echocardiography can often identify the mass and assess hemodynamic impact in real time.
Multimodality imaging (TTE/TEE/CT/MRI) can refine the differential diagnosis of intracardiac masses.
Surgical excision (when pursued) offers definitive tissue diagnosis via pathology.
Removal can eliminate the mechanical source of obstruction and reduce ongoing embolic risk, though outcomes vary by clinician and case.

Limitations (clinical and practical constraints):

Symptoms are frequently nonspecific and can mimic common entities like heart failure, atrial fibrillation–related embolism, or pneumonia.
TTE sensitivity depends on imaging windows and operator experience; small or atypically located masses may be missed.
Distinguishing tumor from thrombus can be challenging in some cases without advanced imaging or pathology.
Embolic complications may occur before diagnosis, and neurologic outcomes can be variable.
Surgical timing and candidacy may be constrained by comorbidities and institutional resources.
Recurrence is possible, particularly in familial/syndromic cases, requiring individualized follow-up strategies.

Follow-up, monitoring, and outcomes

Monitoring after a diagnosis of Atrial Myxoma—and after excision when performed—aims to confirm resolution, identify complications, and watch for recurrence in selected patients.

Factors that can influence outcomes and monitoring intensity include:

Tumor characteristics: Size, mobility, attachment site, and friability influence obstructive physiology and embolic potential.
Clinical presentation: Patients presenting with stroke, heart failure, or hemodynamic instability may have more complex short-term needs.
Rhythm status: Atrial arrhythmias (e.g., atrial fibrillation) may coexist or emerge perioperatively, affecting anticoagulation decisions and follow-up planning (handled case-by-case).
Comorbidities: Age, pulmonary disease, kidney disease, and coronary artery disease can influence operative risk and recovery trajectory.
Syndromic context: Familial disease or Carney complex can prompt closer surveillance and evaluation for additional lesions, with intervals varying by clinician and case.
Post-treatment assessment: Follow-up echocardiography is commonly used to assess chamber function, valve performance, and to ensure no residual or recurrent mass is seen; the exact schedule varies by institution and patient factors.

In general, prognosis after successful removal of a benign myxoma is often favorable, but outcomes depend on pre-existing comorbidities and whether irreversible embolic injury occurred.

Alternatives / comparisons

Because Atrial Myxoma is a tumor, “alternatives” usually refer to alternative diagnoses for a mass or alternative management strategies based on diagnostic certainty and patient risk.

High-level comparisons commonly considered include:

Atrial Myxoma vs atrial thrombus
Thrombus is often associated with atrial fibrillation, left atrial enlargement, low-flow states, or mitral valve disease.
Myxoma more often has a characteristic attachment site and may be pedunculated and mobile; however, overlap exists, and advanced imaging or pathology may be required.
Atrial Myxoma vs infective endocarditis vegetation
Vegetations typically attach to valve leaflets and are supported by infectious features (positive cultures, systemic signs), though constitutional symptoms can overlap.
Myxomas are intracavitary tumors and may present without infection; differentiating features depend on imaging, labs, and overall clinical context.
Atrial Myxoma vs other primary cardiac tumors
Papillary fibroelastoma often involves valves and may cause embolic events.
Malignant tumors (e.g., sarcoma) may show invasive behavior, rapid progression, or pericardial involvement; imaging and pathology guide distinction.
Surgery vs conservative management
Surgical excision is commonly pursued for confirmed myxoma due to obstruction and embolic concerns.
Conservative or delayed approaches may be considered when diagnosis is uncertain, symptoms are minimal, or operative risk is high; decisions vary by clinician and case and typically involve multidisciplinary discussion.
Observation with imaging vs immediate intervention
If imaging suggests thrombus or another reversible cause, a period of medical management with reassessment imaging may be used.
For a mass strongly suggestive of myxoma with concerning features (mobility, symptoms, embolic events), expedited surgical evaluation is often prioritized, recognizing that timing is individualized.

Atrial Myxoma Common questions (FAQ)

Q: Is Atrial Myxoma cancer?
Atrial Myxoma is generally considered a benign primary cardiac tumor. “Benign” refers to histology, but it can still cause serious problems through obstruction or embolization. Malignant cardiac tumors exist, so tissue diagnosis after excision is important when available.

Q: What symptoms does Atrial Myxoma usually cause?
Symptoms commonly fall into obstructive (dyspnea, syncope), embolic (stroke-like deficits), and constitutional (fever, fatigue) categories. Some patients have only one pattern, and others have mixed features. A subset are incidentally found during echocardiography for unrelated reasons.

Q: Does Atrial Myxoma cause chest pain?
Chest discomfort is not the classic presentation, but it can occur in some patients due to hemodynamic stress, arrhythmias, or concurrent cardiac disease. When chest pain is present, clinicians also evaluate for more common causes such as coronary syndromes, pericarditis, or pulmonary pathology. The symptom profile varies by clinician and case.

Q: How is Atrial Myxoma diagnosed?
Echocardiography—starting with transthoracic echocardiography (TTE)—is the most common first step to detect an intracardiac mass and assess hemodynamic effects. Transesophageal echocardiography (TEE), cardiac MRI, or cardiac CT may be used to better define attachment, mobility, and tissue characteristics. Definitive confirmation is typically made by pathology after removal.

Q: What is the usual treatment approach?
When Atrial Myxoma is confirmed or strongly suspected, surgical excision is commonly pursued to remove the mass and obtain tissue diagnosis. The urgency and exact plan depend on symptoms, embolic history, hemodynamics, and operative risk. Adjunct medical management (e.g., treating heart failure symptoms or arrhythmias) may be used as part of overall care.

Q: Will I need general anesthesia for removal?
Surgical excision is typically performed under general anesthesia in an operating room setting. The anesthetic plan depends on patient factors and institutional practice. Specific techniques and monitoring vary by clinician and case.

Q: What does it cost to evaluate or treat Atrial Myxoma?
Costs vary widely by country, hospital system, insurance coverage, imaging modality (TTE vs TEE vs MRI/CT), and whether surgery is performed. Additional factors include length of stay, intensive care needs, and rehabilitation services. For any individual case, costs are institution- and payer-specific.

Q: How long do results last after surgery?
After successful excision of a benign myxoma, removal is typically definitive for that lesion. Recurrence can occur, particularly in familial or syndromic cases, so follow-up strategies are individualized. Long-term outcomes also depend on whether complications like stroke occurred before treatment.

Q: Is it safe to exercise or be active with Atrial Myxoma?
Activity considerations depend on symptoms, tumor features, and embolic or obstructive risk, and should be individualized by the treating team. In general educational terms, dynamic obstruction or recent embolic symptoms are red flags that prompt careful clinical assessment. Guidance varies by clinician and case.

Q: How often is follow-up imaging needed?
There is no single schedule that fits all patients. Follow-up echocardiography is commonly used after treatment and may be repeated periodically when recurrence risk is higher (e.g., familial syndromes, prior recurrence) or when symptoms return. The interval varies by clinician, case, and institutional practice.